What they were paid
Ultragenyx Pharmaceutical Director Compensation Table · all 2 fiscal years held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $70,750 | $199,982 | $207,559 | $0 | $478,291 |
| FY2024 | $68,875 | $200,010 | $199,374 | — | $468,259 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Ultragenyx Pharmaceutical Inc. DEF 14A filed March 27, 2026, accession 0001308179-26-000174, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025Ultragenyx Pharmaceutical pays directors a $50,000 cash retainer and $400,000 in equity.
Committees
FY2025 · as the proxy prints themCompensation · Nominating/Governance (Chair)
The rest of the Ultragenyx Pharmaceutical board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Amrit Ray | Independent Director | $472,541 |
| Corsee D. Sanders | Independent Director | — |
| Daniel G. Welch | Chair of the Board | $508,541 |
| Deborah Dunsire | Independent Director | $475,041 |
| Emil D. Kakkis | Director | $0 |
| Matthew K. Fust | Independent Director | $488,541 |
| Michael Narachi | Independent Director | $490,041 |
The full Ultragenyx Pharmaceutical compensation record
free company briefThis page is one director within Ultragenyx Pharmaceutical's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat